DHTRF 주가 차트
DHTRF 수입
Dri Healthcare Trust
$12.7
0%
$0
종가: Aug 05, 16:00:00 GMT-4
$12.7
0%
$0
애프터마켓: Aug 05, 18:05:48 GMT-4
뒤로
Dri Healthcare Trust (DHTRF) 수입
최신 수익 결과: Q1 '26
보고됨: 2026-05-14
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
DHTRF의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Dri Healthcare Trust DHTRF의 지난 분기 매출 실적은 어땠나요?
Dri Healthcare Trust의 매출 추정치는 얼마인가요?
Dri Healthcare Trust의 수익 품질 점수는 얼마인가요?
Dri Healthcare Trust는 언제 수익을 보고하나요?
Dri Healthcare Trust의 예상 수익은 얼마인가요?
Dri Healthcare Trust은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$12.7
시가
$13.91
일일 범위
$12.7 - $13.91
52주 범위
$9.83 - $13.91
거래량
35
평균 거래량
10.9K
배당수익률
--
EPS(TTM)
-0.90
시가총액
$698.7M
DRI HEALTHCARE TR란 무엇인가요?
DRI Healthcare Trust is an unincorporated open-ended company. The firm's portfolio consists of 29 royalty streams on 23 products that treat conditions in a number of therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, as well as lysosomal storage disorders (LSD) and immunology. Its Royalty Assets include Ekterly, Eylea I, Eylea II, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Spinraza, Vonjo I, Vonjo II, Xolair, Zejula, Zytiga, and others. The Ekterly is an oral on-demand therapy for treating attacks associated with Hereditary Angioedema (HAE). The Eylea I is a vascular endothelial growth factor inhibitor initially indicated for the treatment of neovascular wet age-related macular degeneration. Natpara is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.
